share_log
Reuters ·  Nov 16, 2024 00:01
Arbutus and Barinthus Bio Announce New Data From the IM-Prove II Trial Showing That the Addition of Nivolumab Increased Rates of Hbsag Loss in People With Chronic Hepatitis B
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment